These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
513 related articles for article (PubMed ID: 34571905)
21. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy. Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290 [TBL] [Abstract][Full Text] [Related]
22. Immune microenvironment of experimental rat C6 gliomas resembles human glioblastomas. Gieryng A; Pszczolkowska D; Bocian K; Dabrowski M; Rajan WD; Kloss M; Mieczkowski J; Kaminska B Sci Rep; 2017 Dec; 7(1):17556. PubMed ID: 29242629 [TBL] [Abstract][Full Text] [Related]
23. The immune cell landscape of glioblastoma patients highlights a myeloid-enriched and immune suppressed microenvironment compared to metastatic brain tumors. Musca B; Russo MG; Tushe A; Magri S; Battaggia G; Pinton L; Bonaudo C; Della Puppa A; Mandruzzato S Front Immunol; 2023; 14():1236824. PubMed ID: 37936683 [TBL] [Abstract][Full Text] [Related]
24. Altered Metabolism in Glioblastoma: Myeloid-Derived Suppressor Cell (MDSC) Fitness and Tumor-Infiltrating Lymphocyte (TIL) Dysfunction. Di Ianni N; Musio S; Pellegatta S Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923299 [TBL] [Abstract][Full Text] [Related]
25. Single-Cell Atlas Reveals Complexity of the Immunosuppressive Microenvironment of Initial and Recurrent Glioblastoma. Fu W; Wang W; Li H; Jiao Y; Huo R; Yan Z; Wang J; Wang S; Wang J; Chen D; Cao Y; Zhao J Front Immunol; 2020; 11():835. PubMed ID: 32457755 [TBL] [Abstract][Full Text] [Related]
26. Understanding the glioblastoma tumor microenvironment: leveraging the extracellular matrix to increase immunotherapy efficacy. Collado J; Boland L; Ahrendsen JT; Miska J; Lee-Chang C Front Immunol; 2024; 15():1336476. PubMed ID: 38380331 [TBL] [Abstract][Full Text] [Related]
27. The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy. Desland FA; Hormigo A Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027976 [TBL] [Abstract][Full Text] [Related]
28. The N Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G Front Immunol; 2021; 12():653711. PubMed ID: 34354698 [TBL] [Abstract][Full Text] [Related]
29. Explicating the Pivotal Pathogenic, Diagnostic, and Therapeutic Biomarker Potentials of Myeloid-Derived Suppressor Cells in Glioblastoma. Richard SA Dis Markers; 2020; 2020():8844313. PubMed ID: 33204365 [TBL] [Abstract][Full Text] [Related]
32. Glioblastoma Microenvironment and Invasiveness: New Insights and Therapeutic Targets. Erices JI; Bizama C; Niechi I; Uribe D; Rosales A; Fabres K; Navarro-Martínez G; Torres Á; San Martín R; Roa JC; Quezada-Monrás C Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108208 [TBL] [Abstract][Full Text] [Related]
33. Harnessing the immune system in glioblastoma. Brown NF; Carter TJ; Ottaviani D; Mulholland P Br J Cancer; 2018 Nov; 119(10):1171-1181. PubMed ID: 30393372 [TBL] [Abstract][Full Text] [Related]
34. Mining TCGA database for genes of prognostic value in glioblastoma microenvironment. Jia D; Li S; Li D; Xue H; Yang D; Liu Y Aging (Albany NY); 2018 Apr; 10(4):592-605. PubMed ID: 29676997 [TBL] [Abstract][Full Text] [Related]
35. IGFBP2 promotes immunosuppression associated with its mesenchymal induction and FcγRIIB phosphorylation in glioblastoma. Liu Y; Song C; Shen F; Zhang J; Song SW PLoS One; 2019; 14(9):e0222999. PubMed ID: 31560714 [TBL] [Abstract][Full Text] [Related]
38. A scientometric analysis of immunotherapies for gliomas: Focus on GBM. Xing Y; Yasinjan F; Geng H; He M; Yang M; Gao Y; Zhang J; Zhang L; Guo B Asian J Surg; 2024 Oct; 47(10):4271-4280. PubMed ID: 38448290 [TBL] [Abstract][Full Text] [Related]
39. Myeloid-Derived Suppressive Cells Promote B cell-Mediated Immunosuppression via Transfer of PD-L1 in Glioblastoma. Lee-Chang C; Rashidi A; Miska J; Zhang P; Pituch KC; Hou D; Xiao T; Fischietti M; Kang SJ; Appin CL; Horbinski C; Platanias LC; Lopez-Rosas A; Han Y; Balyasnikova IV; Lesniak MS Cancer Immunol Res; 2019 Dec; 7(12):1928-1943. PubMed ID: 31530559 [TBL] [Abstract][Full Text] [Related]
40. Advances in Nanotechnology-Based Immunotherapy for Glioblastoma. Tang L; Zhang M; Liu C Front Immunol; 2022; 13():882257. PubMed ID: 35651605 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]